DailyIQ
|
Sector:HealthcareAll sectors
Last updated 3 minutes ago

TFX·Teleflex Incorporated

$.
+. (+.%)
After Hours
High
$139.00
Open
$133.27
Market Cap
6.04B
52W High
$139.67
Low
$131.75
P. Close
$131.25
P/E
-
52W Low
$100.18
Fwd P/E
106.61
DailyIQ Est.
$147.67
Technical Score (1D)
91
BUY
News Sentiment
50
MIXED
Mizuho’s latest research note on Teleflex (TFX) lifts the price target from $140 to $145 while keeping a neutral rating, signaling that the bank now sees a modest upside potential if the company delivers on its earnings guidance. The upgrade reflects confidence in Teleflex’s current valuation and the stability of its earnings profile, suggesting that the firm’s fundamentals are solid but not yet presenting a clear catalyst. Because the rating remains neutral, traders should not expect a sudden rally but can anticipate a steady, potentially upward‑trending range as the market digests the new target. Over the next 1–10 trading days, the stock may trade within a tighter band as investors weigh the modest target bump against the lack of an immediate earnings surprise. The key watch item is Teleflex’s upcoming earnings release, where any deviation from guidance could quickly shift sentiment. Additionally, monitor any updates on the company’s cost structure or product demand, as changes there could influence the earnings outlook and justify the higher target. Keep an eye on broader medical device sector movements, as Teleflex’s performance is often tied to overall industry demand and regulatory developments. Finally, watch for any commentary from other analysts that might either reinforce or challenge Mizuho’s neutral stance, as consensus shifts can prompt quick adjustments in the stock’s trajectory.
Earnings Summary
Teleflex Incorporated is a global medical device manufacturer that specializes in single‑use products across vascular access, interventional, anesthesia, surgical, urology, and respiratory applications, positioning it within the broader medical instruments and supplies sector. In the most recent two quarters, Teleflex reported a decline in both revenue and earnings per share, with Q4 2025 revenue falling to $568.98 million and EPS to $1.93 versus Q2 2025 revenue of $780.89 million and EPS of $3.73; the Q1 2026 figures continued this downward trend with revenue of $548.26 million and EPS of $1.39, compared to Q3 2025 revenue of $892.90 million and EPS of $3.67. Despite the recent downturn, Teleflex has historically beaten analyst estimates in five of the six quarters examined, with the sole miss occurring in Q4 2025 when EPS fell short of the $3.77 estimate; revenue has shown a mixed trajectory, rising in Q2 and Q3 2025 before declining in the subsequent quarters. Recent coverage by BMO Capital and Argus Research has introduced fresh analyst optimism, with an Outperform rating and a $159 price target, while the company’s initiation of patient enrollment in the BIOMAG‑III study of its Freesolve magnesium scaffold has added a potential catalyst that could influence future valuation; elevated options activity and implied volatility further underscore market anticipation of forthcoming data. Investors should watch for the Q2 2026 earnings release, paying particular attention to guidance on revenue, EPS, and raw‑material cost management, as well as the first safety and efficacy data from the BIOMAG‑III study, which could materially affect Teleflex’s competitive positioning and margin outlook.

EPS

EstBeatMiss
$0.84$1.67$2.50$3.33$4.15Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.27 - -
Q1'26$1.22$1.39+13.6%
Q4'25$3.77$1.93-48.8%
Q3'25$3.38$3.67+8.6%
Q2'25$3.37$3.73+10.8%
Q1'25$2.88$2.91+0.9%

Revenue

EstBeatMiss
$480M$607M$734M$860M$987MQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$565M - -
Q1'26$539M$548M+1.8%
Q4'25$928M$569M-38.7%
Q3'25 - $893M -
Q2'25 - $781M -
Q1'25 - $701M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

TFX Stock Snapshot

TFX is currently trading at $131.75, giving Teleflex Incorporated a market cap of 6.04B. Today's range spans $131.75–$139.00, with shares opening at $133.27 and moving up $0.50 (0.4%) from the prior close. DailyIQ's technical score sits at 91/100 (BUY) with a news sentiment reading of 50/100.

Over the past year TFX has traded between $100.18 and $139.67 - the current price is +31.5% off the 52-week low and -5.7% from the high. 19 analysts cover the stock with a Hold consensus and a mean 12-month target of $147.20 (range $135.00–$160.00), implying upside of +11.7%.

The bullish technical and neutral sentiment alignment for TFX is especially notable at the small-cap level. Score: 91/100 (BUY). Sentiment: 50/100. Price: $131.75 (in the upper portion of its 52-week range in $100.18–$139.67). With 6.04B in Healthcare market cap, the primary risk isn't the setup - it's execution. Small-cap Healthcare names with this kind of profile move fast once momentum builds, and the entry point matters more than it does at larger scales.

The combination of a BUY technical signal (91/100) and neutral news sentiment (50/100) in a small-cap like TFX (6.04B, Healthcare) creates the kind of setup that shows up in small-cap momentum screens used by growth-oriented funds. At $131.75 (in the upper portion of its 52-week range in $100.18–$139.67), the stock is not yet crowded — which means the entry risk-reward is better than it will be if the technical and sentiment setup persists and attracts wider institutional attention.